Global Glutamate Antagonist Market Growth 2023-2029

Global Glutamate Antagonist Market Growth 2023-2029

Glutamate Antagonists work by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly classified into two main subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors.
LPI (LP Information)' newest research report, the “Glutamate Antagonist Industry Forecast” looks at past sales and reviews total world Glutamate Antagonist sales in 2022, providing a comprehensive analysis by region and market sector of projected Glutamate Antagonist sales for 2023 through 2029. With Glutamate Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glutamate Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Glutamate Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glutamate Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glutamate Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glutamate Antagonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glutamate Antagonist.
The global Glutamate Antagonist market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glutamate Antagonist players cover Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, Purdue Biopharma, Relmada Therapeutics, BioCrea GmbH and Cerecor Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glutamate Antagonist market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Ionic
Non Ionic
Segmentation by application
Hospitals
Clinics
Laboratory
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Artemis Neuroscience
VistaGen Therapeutics
Rottapharm Madaus
Amorsa Therapeutics
Newron Pharmaceuticals
Purdue Biopharma
Relmada Therapeutics
BioCrea GmbH
Cerecor Inc.
NeurOp Inc.
UCB SA
Novartis AG
Luc Therapeutics Inc.
Evotec AG
Key Questions Addressed in this Report
What is the 10-year outlook for the global Glutamate Antagonist market?
What factors are driving Glutamate Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glutamate Antagonist market opportunities vary by end market size?
How does Glutamate Antagonist break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.